Risk
Review APOE status and a broader Alzheimer's polygenic risk score rather than relying on a single gene alone.
Genetic Resilience Analysis is NeuroAge's inherited-risk and resilience product, covering Alzheimer's risk, other neurodegenerative disorders, longevity and resilience markers, medically actionable pharmacogenomic genes, broader disease risks, and personalized recommendations based on your genetic profile.
Use qualifying whole-genome data you already have or add genome sequencing at checkout, then review personalized recommendations in the context of your inherited risk profile.
Genome Sequencing
+ $550
Sequence your genome for the Genetic Resilience analysis (30X whole-genome sequencing)
Inherited risk does not determine your future, but it can tell you where to pay closer attention.
NeuroAge uses genetics to help clients understand inherited Alzheimer's risk, other neurodegenerative disorders, protective or longevity-associated variants, medication-relevant genes, and broader disease risks that can matter clinically.
The product is especially useful for people with family history, those who already have sequencing data, or those who want to build a more complete prevention baseline.
Review APOE status and a broader Alzheimer's polygenic risk score rather than relying on a single gene alone.
See longevity and protective variants that can add nuance to your brain-aging profile.
Surface medically actionable and pharmacogenomic markers that can be relevant far beyond brain health alone.
The genetics page is built for people who want clinical-grade interpretation and broader coverage.
Get more detailed inherited-risk information if Alzheimer's or related disease runs in your family.
Put whole-genome data to work with brain-aging and disease-risk interpretation.
Combine genetics with MRI, biomarkers, or NeuroGames for more complete context.
NeuroAge's science and FAQ materials describe a genetics product that extends well beyond a single Alzheimer's risk allele.
For Alzheimer's, NeuroAge calculates a polygenic risk score across 41 variants rather than reporting APOE alone. The genetics panel also covers broader neurodegenerative markers, protective or longevity-associated genes, and personalized recommendations grounded in the patterns found in your profile.
The same materials also describe medically actionable or pharmacogenomic genes such as MTHFR, CYP2C19, CYP2C9, SLCO1B1, VKORC1, and HLA-B*15:02, along with broader disease-risk areas including coronary artery disease, atrial fibrillation, osteoporosis, colorectal cancer, primary open-angle glaucoma, psoriasis, Crohn's disease, and ovarian cancer.
The dashboard helps organize genetic findings into a structure that is easier to discuss and act on.
See Alzheimer's-related findings alongside broader resilience and longevity markers.
Review pharmacogenomic and actionable genes in one place.
Use the dashboard as a bridge into personalized recommendations, coaching, or other NeuroAge products if desired.

What NeuroAge customers are saying across imaging, testing, and coaching.
No. NeuroAge's genetics materials describe APOE plus a 41-variant Alzheimer's polygenic risk score, broader neurodegenerative markers, longevity-associated genes, and medically actionable pharmacogenomic markers.
This analysis is designed for whole-genome or clinical-grade sequencing data rather than consumer genotyping files such as 23andMe alone.
You can add genome sequencing at checkout if you do not already have qualifying data available.
Yes. NeuroAge's current science and FAQ materials describe pharmacogenomic genes and disease-risk areas beyond Alzheimer's, including cardiovascular, bone, cancer, eye, and immune-related categories.
Review APOE, polygenic risk, broader neurodegenerative and disease risks, and personalized recommendations in one genetics-focused product.